Alimentary Pharmacology & Therapeutics最新文献

{"title":"Editorial: Beyond DNA Suppression: HBV RNA as a Predictor of Hepatocarcinogenesis.","authors":"Toshifumi Tada","doi":"10.1111/apt.70497","DOIUrl":"https://doi.org/10.1111/apt.70497","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"31 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145710836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Message From the Editors","authors":"Colin W. Howden,&nbsp;Rohit Loomba","doi":"10.1111/apt.70454","DOIUrl":"https://doi.org/10.1111/apt.70454","url":null,"abstract":"<p>Welcome to the first edition of <i>AP&amp;T</i> for 2026.</p><p>Our most recent 2-year impact factor of 6.7 keeps <i>AP&amp;T</i> in 18th position among 147 journals in our field. We congratulate the authors of the 10 papers published in 2024 that were most highly cited in 2025 [<span>1-10</span>], and of the 10 most frequently downloaded papers between October 2024 and September 2025 [<span>11-20</span>]. As expected, steatotic liver disease and IBD continue to be highly important topics for <i>AP&amp;T</i>.</p><p>Excluding editorials and letters, we received 2,020 new submissions between January and September 2025, and ultimately accepted 153 (7.6%). Decisions on individual submissions are made objectively and are based on quality and likely relevance to the readership. We strive to maintain a balance between hepatology and ‘luminal’ gastroenterology. For some papers we are unable to accept, we offer transfer—as appropriate—to <i>Neurogastroenterology and Motility</i>, <i>Basic &amp; Clinical Pharmacology &amp; Toxicology</i>, or <i>Pharmacology Research and Perspectives</i>.</p><p>During 2025, Cynthia Seow stepped down from her position as Associate Editor and will be replaced by Tim Card (University of Nottingham, UK). Alex Ford also stepped down at the end of 2025 after 14 years with the journal. Alex will be replaced by Chris Black (University of Leeds, UK). We thank Cynthia and Alex for their service and look forward to working with Tim and Chris. We congratulate Alex on his new position as Deputy Editor-in-Chief of <i>Gut</i>.</p><p>One change made in 2025 was the discontinuation of the Research Communication option. In 2026, submissions to <i>AP&amp;T</i>, as well as the peer-review process, are now handled through our publisher's Research Exchange (ReX) system. Doubtless, there will be a learning curve but we hope that this will streamline the submission and review process and provide yet more safeguards against such issues as plagiarism, image manipulation and other forms of academic misconduct.</p><p>Please continue to consider <i>AP&amp;T</i> for your original research and review articles in digestive and liver disease. Authors with a proposal for a review article may contact us in advance to discuss its content and scope. While we cannot accept many of the submissions we receive, we will provide a scrupulously fair and transparent review process and a rapid decision. In fact, <i>AP&amp;T</i> continues to have the shortest decision times among journals in our field.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"63 1","pages":"4-5"},"PeriodicalIF":6.7,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70454","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145706533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AP&T: Editors' Declarations of Interest","authors":"","doi":"10.1111/apt.70468","DOIUrl":"https://doi.org/10.1111/apt.70468","url":null,"abstract":"&lt;p&gt;\u0000 &lt;b&gt;\u0000 &lt;i&gt;Professor C. W. Howden, Editor&lt;/i&gt;\u0000 &lt;/b&gt;\u0000 &lt;/p&gt;&lt;p&gt;Professor Howden is a consultant/speaker for Phathom Pharmaceuticals, consultant/speaker for RedHill Biopharma, consultant/speaker for Meridian Diagnostics, consultant for Sebela/Braintree and consultant for ISOThrive. He has stock options in EndoStim.&lt;/p&gt;&lt;p&gt;\u0000 &lt;b&gt;\u0000 &lt;i&gt;Professor R. Loomba, Editor&lt;/i&gt;\u0000 &lt;/b&gt;\u0000 &lt;/p&gt;&lt;p&gt;Professor Loomba serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics. He has stock options in Sagimet biosciences. In addition, his institution received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals. He is also the co-founder of LipoNexus Inc.&lt;/p&gt;&lt;p&gt;\u0000 &lt;b&gt;\u0000 &lt;i&gt;Professor G. M. Dusheiko, Associate Editor&lt;/i&gt;\u0000 &lt;/b&gt;\u0000 &lt;/p&gt;&lt;p&gt;Professor Dusheiko serves on independent data safety monitoring boards for Aligos, Arbutus, Glaxo Smith Kline, Janssen and Gilead. In the past two years, he has received honoraria from Arbutus, Antios, Aligos and Gilead Sciences, and he serves as an advisor to the National Medical Research Council, Singapore; the TherVacB Consortium (European Horizon Grant); and the A-Tango Consortium (EUH2020 grant).&lt;/p&gt;&lt;p&gt;\u0000 &lt;b&gt;\u0000 &lt;i&gt;Professor G. L.-H. Wong, Associate Editor&lt;/i&gt;\u0000 &lt;/b&gt;\u0000 &lt;/p&gt;&lt;p&gt;Professor Wong has served as an advisory committee member for AstraZeneca, Barinthus Biotherapeutics, Gilead Sciences, GlaxoSmithKline, Janssen and Virion; has served as a speaker for Abbott, AbbVie, Ascletis Pharmaceuticals, Bristol-Myers Squibb, Echosens, Ferring, Gilead Sciences, GlaxoSmithKline, Janssen and Roche; and has received research grants from Gilead Sciences.&lt;/p&gt;&lt;p&gt;\u0000 &lt;b&gt;\u0000 &lt;i&gt;Professor R. B. Gearry, Associate Editor&lt;/i&gt;\u0000 &lt;/b&gt;\u0000 &lt;/p&gt;&lt;p&gt;Professor Gearry is, or has been, a member of advisory boards for AbbVie, Janssen, Schering-Plough, Zespri, Baxter and Celltrion. He has received honoraria or travel grants from AbbVie, Janssen, Schering Plough, Zespri, Ferring and Celltrion. He has received research grants for investigator-initiated studies from AbbVie, Janssen, Goodman-Fielder, Comvita and Zespri.&lt;/p&gt;&lt;p&gt;\u0000 &lt;b&gt;\u0000 &lt;i&gt;Dr. S. Subramanian, Associate Editor&lt;/i&gt;\u0000 &lt;/b&gt;\u0000 &lt;/p&gt;&lt;p&gt;Dr. Subramanian is/has been on the speaker bureau for Abbvie, Bristol-Myers Squibb, Celltrio","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"63 1","pages":"6-7"},"PeriodicalIF":6.7,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70468","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145706531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: MetALD and Risk of Gastrointestinal Cancer-What Can We Learn From Japan? Authors' Reply.","authors":"Nobuharu Tamaki,Takefumi Kimura,Shun-Ichi Wakabayashi,Masayuki Kurosaki","doi":"10.1111/apt.70489","DOIUrl":"https://doi.org/10.1111/apt.70489","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"372 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter on ‘Meta-Analysis: Mortality Trends and Risk Factors in Severe Alcohol-Associated Hepatitis’—Authors' Reply","authors":"Francisco Idalsoaga,&nbsp;Luis Antonio Díaz,&nbsp;Stephen Hoang,&nbsp;Mohammad Qasim Khan,&nbsp;Juan Pablo Arab","doi":"10.1111/apt.70488","DOIUrl":"10.1111/apt.70488","url":null,"abstract":"&lt;p&gt;We thank Zhao for his thoughtful letter regarding our meta-analysis of short-term mortality in severe alcohol-associated hepatitis (sAH) [&lt;span&gt;1&lt;/span&gt;]. Our primary objective was to estimate pooled mortality at 28, 60 and 90 days and to assess temporal trends and risk factors for short-term mortality in sAH. We found high mortality, with 90-day mortality of 43.7% (95% CI: 34.6–53.3). Therefore, our study confirmed that sAH confers a high risk of mortality, without statistically credible improvement in recent decades [&lt;span&gt;2&lt;/span&gt;]. However, we respectfully disagree with some aspects mentioned as potential limitations.&lt;/p&gt;&lt;p&gt;It was argued that the structural heterogeneity of ‘standard care’ invalidates our decade-based time-trend analyses. Since the landmark Maddrey study in 1978 [&lt;span&gt;3&lt;/span&gt;], corticosteroids have been widely used as the only therapy with demonstrated benefit in sAH [&lt;span&gt;4&lt;/span&gt;]. In our dataset, only one early study used diet as a comparator, whereas most trials employed a placebo. The use of ‘prophylactic antibiotics’ as standard care is also incorrect, as no mortality benefit has been shown, and none of the included studies used antibiotics as a control arm. We acknowledge that control arm definitions evolved across decades, reflecting advances in supportive care, and that this heterogeneity complicates temporal comparisons. Despite this, the lack of improvement in 90-day mortality across recent decades, where standards of care are more comparable, remains concerning. Moreover, the statement of ‘no statistically credible improvement’ refers to decade-wise comparisons from the 1980s onward, where 95% credible intervals largely overlap.&lt;/p&gt;&lt;p&gt;Regarding model selection, we agree that follow-up time is biologically expected to correlate with mortality; this is why it was pre-specified as a key covariate. The role of the meta-regression was not to ‘discover’ that longer follow-up increases deaths, but to separate horizon effects from calendar-time or treatment-era effects in single-arm pooled data. In this framework, publication year did not provide additional explanatory power once follow-up was accounted for, and the AIC-guided choice of a parsimonious model was used to avoid overfitting sparse and heterogeneous study-level covariates. However, our complementary Bayesian analyses examining mortality across decades show overlapping credible intervals from the 1980s onward, supporting the overall finding that progress has plateaued despite four decades of advancing supportive care.&lt;/p&gt;&lt;p&gt;The robustness of the MELD–mortality association was also questioned. We acknowledge limitations due to missing data and reporting bias, and therefore classified all meta-regressions as exploratory and downgraded certainty using a GRADE-based approach. Nevertheless, the positive association observed is consistent with large contemporary cohorts in which MELD shows superior prognostic performance over mDF [&lt;span&gt;5, 6&lt;/span&gt;]. Finally, w","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"63 2","pages":"316-317"},"PeriodicalIF":6.7,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70488","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: MetALD and Risk of Gastrointestinal Cancer-What Can We Learn From Japan?","authors":"Hannes Hagström,Ying Shang","doi":"10.1111/apt.70477","DOIUrl":"https://doi.org/10.1111/apt.70477","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"2 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport","authors":"Emmanuel Pio Pastore","doi":"10.1111/apt.70464","DOIUrl":"https://doi.org/10.1111/apt.70464","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"203 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145673960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Villin-1-A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation.","authors":"David Tornai,Boglarka Balogh,Aniko Csillag,Andras Budai,Andras Kiss,Peter Antal-Szalmas,Gabor Mehes,Lukacs Barath,Tamas Tornai,Istvan Tornai,Zsuzsanna Vitalis,Nora Sipeki,Tamas Dinya,Attila Enyedi,Florian A Rosenberger,Wim Laleman,Minneke J Coenraad,Ferran Aguilar,Joan Claria,Richard Moreau,Jonel Trebicka,Maria Papp, ","doi":"10.1111/apt.70481","DOIUrl":"https://doi.org/10.1111/apt.70481","url":null,"abstract":"BACKGROUNDGut barrier dysfunction contributes to acute decompensation (AD) of cirrhosis progression but, it is not acknowledged in severity or prognostic scores due to a lack of appropriate assessment tools.AIMWe investigated serum villin-1 (VIL1), an epithelial brush-border associated actin-binding protein, as a non-invasive marker for gut injury and prognosis in AD cirrhosis.METHODSSerum VIL1 was measured in 338 cirrhosis patients (discovery n = 130, validation n = 208, including acute-on-chronic liver failure [ACLF]) from MICROB-PREDICT cohorts and 50 healthy controls (HC). Duodenal biopsies (n = 49 patients, n = 11 HC) were assessed for tissue VIL1 via immunohistochemistry. Serum cytokine profiling linked serum VIL1 levels to systemic inflammation.RESULTSCompared to HC, both serum and tissue VIL1 levels were lower in stable AD patients. However, serum VIL1 progressively increased with AD severity, peaking in ACLF. Serum VIL1 was associated with 90-day mortality (AUROC: 0.721, p < 0.001; similar to MELD: 0.722, p < 0.001). A cut-off > 12.79 ng/mL enhanced the prognostic accuracy provided by severe disease stage, defined as CLIF-C AD score ≥ 50 or ACLF (low VIL1: 17.5% vs. high VIL1: 53.6% mortality). This threshold was associated with increased systemic inflammation, suggesting enhanced bacterial translocation. VIL1 was an independent predictor of 90-day mortality (HR: 2.52, CI: 1.648-3.848, p < 0.001) in Cox regression. All findings were confirmed in the validation cohort.CONCLUSIONSerum VIL1 is a non-invasive indicator of gut barrier damage and short-term mortality in AD cirrhosis. Incorporating VIL1 assessment into risk stratification methods improves prognostic accuracy by capturing an essential, yet previously overlooked component of disease progression.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"113 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145664036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial for ‘Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance, and Expansion’","authors":"Cameron Kendall,&nbsp;Akhilesh Swaminathan","doi":"10.1111/apt.70484","DOIUrl":"10.1111/apt.70484","url":null,"abstract":"&lt;p&gt;The treat-to-target approach in inflammatory bowel disease (IBD) emphasises the importance of serial, non-invasive monitoring of disease activity that can be achieved by using a range of modalities [&lt;span&gt;1&lt;/span&gt;]. Among these, intestinal ultrasound (IUS) shows promise by virtue of its potential for seamless integration into routine clinic appointments, relatively low cost, repeatability and high patient approval [&lt;span&gt;2&lt;/span&gt;]. Despite these advantages, global uptake of IUS has been hampered by several factors, one of which includes concerns around the relatively smaller evidence base for IUS for assessment of IBD in comparison to traditional modalities such as magnetic resonance enterography (MRE), ileocolonoscopy and blood and faecal biomarkers. We read with interest the recent article by Lu et al. [&lt;span&gt;3&lt;/span&gt;] which provided a high-level overview of the current state of IUS research while highlighting gaps in the current literature.&lt;/p&gt;&lt;p&gt;There has been an explosion of interest in IUS in recent years [&lt;span&gt;4&lt;/span&gt;]. Consequently, there are now a multitude of sonographic techniques and scoring systems [&lt;span&gt;5&lt;/span&gt;] that have been developed for clinical use. Lu et al. [&lt;span&gt;3&lt;/span&gt;] highlighted the lack of international consensus regarding the optimal use of these indices, especially in relation to monitoring disease response to IBD medications, the assessment of intestinal segments post-resection, and in the assessment of paediatric populations who may benefit significantly from the non-invasive nature of IUS. Additionally, the available IUS indices need to be refined for easy bedside use, demonstrate inter- and intra-operator reliability, and be easily interpreted by different clinicians—which includes ongoing validation in comparison to ileocolonoscopy, MRE and capsule endoscopy. Optimal clinical use of IUS will also be dependent on the synergy of this modality with other non-invasive measures of IBD such as faecal and blood biomarkers, which best reflect real-world practice. The utility of combining these assessment tools for predicting the longitudinal trajectory of IBD also remains unanswered.&lt;/p&gt;&lt;p&gt;Given the growing burden of IBD worldwide [&lt;span&gt;6&lt;/span&gt;], there needs to be ongoing consideration for the use of cost-effective and sustainable modalities for IBD assessment. Thus, additional avenues for ongoing research should consider the reproducibility of IUS indices/assessment from handheld devices to high-end machines [&lt;span&gt;7&lt;/span&gt;], and alignment and optimisation of training pathways worldwide. Ongoing endeavours in this space are underway through organisations such as the International Bowel Ultrasound Group (IBUS), the Gastrointestinal Network of Intestinal Ultrasound (GENIUS) and the Intestinal Ultrasound Group of the United States and Canada (iUSCAN).&lt;/p&gt;&lt;p&gt;There is little doubt that IUS holds a valuable and growing role in IBD assessment. Its full potential will probably be apparent once it is integrated alongs","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"63 3","pages":"437-438"},"PeriodicalIF":6.7,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70484","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145651138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intestinal Ultrasound Transmural Healing Was Associated With Improved Long‐Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study","authors":"Clara Yzet, Amélie Plancke, Franck Brazier, Lucien Grados, Elise Derval, Louise Ghilardi, Momar Diouf, Adrien Ollier, Mathurin Fumery","doi":"10.1111/apt.70479","DOIUrl":"https://doi.org/10.1111/apt.70479","url":null,"abstract":"Background STRIDE II guidelines recognise endoscopic healing as a main therapeutic target in Crohn's disease (CD). Nevertheless, transmural healing (TH) could reduce the risk of long‐term complications. Aim To assess the impact of intestinal ultrasound (IUS) TH on CD long‐term among patients with endoscopic healing. Method We conducted a prospective study of consecutive patients with CD who underwent colonoscopy with endoscopic healing (CDEIS &lt; 4) and IUS. IUS TH was defined by a bowel wall thickness &lt; 3 mm without colour Doppler signal. The primary endpoint was CD relapse (drug intensification, initiation of steroid, CD‐related hospitalization or surgery, luminal stricture/fistula or perianal CD). Results We included 93 patients. IUS TH was observed in 73%. No difference in median IBD‐risk score was observed among patients with and without IUS TH (22 (IQR 7–41) vs. 30 (IQR 13–55); <jats:italic>p</jats:italic> = 0.15). After a median follow‐up of 22.5 months (IQR 19.3–23.7), the cumulative risk of relapse was significantly lower among patients with IUS healing (17% vs. 48%; <jats:italic>p</jats:italic> = 0.007). The benefit of TH remained when considering only patients with complete endoscopic healing (CDEIS = 0) (12‐month relapse rate, 2% vs. 33%; <jats:italic>p</jats:italic> = 0.03). The risk of CD‐related hospitalization (3% vs. 16%; <jats:italic>p</jats:italic> = 0.04) and perianal CD (3% vs. 16%; <jats:italic>p</jats:italic> = 0.04) were significantly lower among patients with IUS healing. In multivariate analysis, the absence of TH remained the only independent factor associated with CD relapse (hazard ratio 2.6 (1.1–6.2); <jats:italic>p</jats:italic> = 0.03). Conclusion IUS TH was associated with improved long‐term outcomes with lower risks of CD relapse, hospitalization, and perianal CD.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"603 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145651142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}